This year’s rideATAXIA Dallas, a cycling event that raises money to support research into treatments for Friedreich’s ataxia,…
Articles by Marisa Wexler, MS
Reata Pharmaceuticals is planning to ask the U.S. Food and Drug Administration (FDA) to approve omaveloxolone to treat people…
Researchers have developed a new system that might better measure walking or gait problems in people with Friedreich’s ataxia…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
The U.S. Food and Drug Administration has put a hold on the clinical development of CTI-1601, an investigational treatment for…
Leriglitazone, an oral treatment candidate for Friedreich’s ataxia (FA), can increase frataxin levels and reduce neuronal degeneration in cell and…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…
The Friedreich’s Ataxia Research Alliance (FARA), the CureFA Foundation, and fara Australia are supporting four research projects…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
IXICO has entered a five-year collaboration with the Friedreich’s Ataxia Research Alliance (FARA) and joined the TRACK-FA Neuroimaging…